These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 36636443)

  • 41. [Outcome analysis of patients undergoing percutaneous coronary intervention with or without prior coronary artery bypass grafting operation].
    Song Y; Xu JJ; Tang XF; Wang HH; Liu R; Jiang P; Jiang L; Gao LJ; Zhang Y; Song L; Xu LJ; Zhao XY; Gao Z; Chen J; Gao RL; Qiao SB; Yang YJ; Xu B; Yuan JQ
    Zhonghua Xin Xue Guan Bing Za Zhi; 2017 Jul; 45(7):559-565. PubMed ID: 28738483
    [No Abstract]   [Full Text] [Related]  

  • 42. Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer.
    Kawachi H; Yamada T; Tamiya M; Negi Y; Goto Y; Nakao A; Shiotsu S; Tanimura K; Takeda T; Okada A; Harada T; Date K; Chihara Y; Hasegawa I; Tamiya N; Ishida M; Katayama Y; Morimoto K; Iwasaku M; Tokuda S; Kijima T; Takayama K
    JAMA Netw Open; 2023 Jul; 6(7):e2322915. PubMed ID: 37432682
    [TBL] [Abstract][Full Text] [Related]  

  • 43. 5-year outcomes following percutaneous coronary intervention with drug-eluting stent implantation versus coronary artery bypass graft for unprotected left main coronary artery lesions the Milan experience.
    Chieffo A; Magni V; Latib A; Maisano F; Ielasi A; Montorfano M; Carlino M; Godino C; Ferraro M; Calori G; Alfieri O; Colombo A
    JACC Cardiovasc Interv; 2010 Jun; 3(6):595-601. PubMed ID: 20630452
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Incidence of immune checkpoint inhibitor mediated cardiovascular toxicity: A systematic review and meta-analysis.
    Malaty MM; Amarasekera AT; Li C; Scherrer-Crosbie M; Tan TC
    Eur J Clin Invest; 2022 Dec; 52(12):e13831. PubMed ID: 35788986
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cardiovascular adverse events induced by immune checkpoint inhibitors: A real world study from 2018 to 2022.
    Wu S; Bai H; Zhang L; He J; Luo X; Wang S; Fan G; Sun N
    Front Cardiovasc Med; 2022; 9():969942. PubMed ID: 36035942
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Percutaneous coronary intervention with drug-eluting stents versus coronary artery bypass grafting in left main coronary artery disease: an individual patient data meta-analysis.
    Sabatine MS; Bergmark BA; Murphy SA; O'Gara PT; Smith PK; Serruys PW; Kappetein AP; Park SJ; Park DW; Christiansen EH; Holm NR; Nielsen PH; Stone GW; Sabik JF; Braunwald E
    Lancet; 2021 Dec; 398(10318):2247-2257. PubMed ID: 34793745
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Identification of Pathogenic Immune Cell Subsets Associated With Checkpoint Inhibitor-Induced Myocarditis.
    Zhu H; Galdos FX; Lee D; Waliany S; Huang YV; Ryan J; Dang K; Neal JW; Wakelee HA; Reddy SA; Srinivas S; Lin LL; Witteles RM; Maecker HT; Davis MM; Nguyen PK; Wu SM
    Circulation; 2022 Jul; 146(4):316-335. PubMed ID: 35762356
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immune-related adverse events after immune checkpoint inhibitor exposure in adult cancer patients with pre-existing autoimmune diseases.
    Pizuorno Machado A; Shatila M; Liu C; Wang J; Altan M; Zhang HC; Thomas A; Wang Y
    J Cancer Res Clin Oncol; 2023 Aug; 149(9):6341-6350. PubMed ID: 36752908
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Efficacy comparison of 3 strategies for real-world stable coronary artery disease patients with three-vessel disease].
    Liu R; Jiang L; Xu LJ; Tian J; Zhao XY; Zhang Y; Xu JJ; Song Y; Wang HH; Gao Z; Song L; Yuan JQ
    Zhonghua Xin Xue Guan Bing Za Zhi; 2017 Dec; 45(12):1049-1057. PubMed ID: 29325365
    [No Abstract]   [Full Text] [Related]  

  • 51. Ophthalmic Immune-Related Adverse Events after Anti-CTLA-4 or PD-1 Therapy Recorded in the American Academy of Ophthalmology Intelligent Research in Sight Registry.
    Sun MM; Kelly SP; Mylavarapu Bs AL; Holland GN; Coleman AL; Yu F; Hsu Ms S; Lum F; Gordon LK
    Ophthalmology; 2021 Jun; 128(6):910-919. PubMed ID: 33166553
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Staged complete revascularization or culprit-only percutaneous coronary intervention for multivessel coronary artery disease in patients with ST-segment elevation myocardial infarction and diabetes.
    Cui K; Lyu S; Liu H; Song X; Yuan F; Xu F; Zhang M; Wang W; Zhang M; Zhang D; Tian J
    Cardiovasc Diabetol; 2019 Sep; 18(1):119. PubMed ID: 31530274
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis.
    Dolladille C; Akroun J; Morice PM; Dompmartin A; Ezine E; Sassier M; Da-Silva A; Plane AF; Legallois D; L'Orphelin JM; Alexandre J
    Eur Heart J; 2021 Dec; 42(48):4964-4977. PubMed ID: 34529770
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparative Effectiveness of Medical Therapy, Percutaneous Revascularization, and Surgical Coronary Revascularization in Cardiovascular Risk Subgroups of Patients With CKD: A Retrospective Cohort Study of Medicare Beneficiaries.
    Charytan DM; Natwick T; Solid CA; Li S; Gong T; Herzog CA
    Am J Kidney Dis; 2019 Oct; 74(4):463-473. PubMed ID: 31255335
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Incidence, Clinical Characteristics, and Predictors of Cardiovascular Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors.
    Isawa T; Toi Y; Sugawara S; Taguri M; Toyoda S
    Oncologist; 2022 May; 27(5):e410-e419. PubMed ID: 35348766
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Differential Rates and Clinical Significance of Periprocedural Myocardial Infarction After Stenting or Bypass Surgery for Multivessel Coronary Disease According to Various Definitions.
    Cho MS; Ahn JM; Lee CH; Kang DY; Lee JB; Lee PH; Kang SJ; Lee SW; Kim YH; Lee CW; Park SW; Park DW; Park SJ
    JACC Cardiovasc Interv; 2017 Aug; 10(15):1498-1507. PubMed ID: 28797425
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Risk of Ophthalmic Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.
    Hou YL; Wang DY; Hu JX; Tian RY; Wang W; Su Q; Li H; Wang YL
    Ocul Immunol Inflamm; 2022 Aug; 30(6):1449-1459. PubMed ID: 33970759
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Stroke Rates Following Surgical Versus Percutaneous Coronary Revascularization.
    Head SJ; Milojevic M; Daemen J; Ahn JM; Boersma E; Christiansen EH; Domanski MJ; Farkouh ME; Flather M; Fuster V; Hlatky MA; Holm NR; Hueb WA; Kamalesh M; Kim YH; Mäkikallio T; Mohr FW; Papageorgiou G; Park SJ; Rodriguez AE; Sabik JF; Stables RH; Stone GW; Serruys PW; Kappetein AP
    J Am Coll Cardiol; 2018 Jul; 72(4):386-398. PubMed ID: 30025574
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of diabetes mellitus on patients with unprotected left main coronary artery lesion disease treated with either percutaneous coronary intervention or coronary-artery bypass grafting.
    Luo Y; Yu X; Chen F; Du X; He J; Gao Y; Zhang X; Zhang Y; Ren X; Lv S; Ma C
    Coron Artery Dis; 2012 Aug; 23(5):322-9. PubMed ID: 22750912
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Long-term clinical outcomes after percutaneous coronary intervention versus coronary artery bypass grafting for ostial/midshaft lesions in unprotected left main coronary artery from the DELTA registry: a multicenter registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment.
    Naganuma T; Chieffo A; Meliga E; Capodanno D; Park SJ; Onuma Y; Valgimigli M; Jegere S; Makkar RR; Palacios IF; Costopoulos C; Kim YH; Buszman PP; Chakravarty T; Sheiban I; Mehran R; Naber C; Margey R; Agnihotri A; Marra S; Capranzano P; Leon MB; Moses JW; Fajadet J; Lefevre T; Morice MC; Erglis A; Tamburino C; Alfieri O; Serruys PW; Colombo A
    JACC Cardiovasc Interv; 2014 Apr; 7(4):354-61. PubMed ID: 24630886
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.